SAN DIEGO — Illumina, Inc. (NASDAQ:ILMN) today announced estimated first quarter revenue of approximately $270 million. This number is based on a preliminary estimate and remains subject to review by Illumina’s independent registered public accounting firm. Analysis of the remainder of the income statement is incomplete, but the company expects non-GAAP EPS to be at or above current consensus estimates. Full quarterly results will be announced later this month.

“We are very pleased with our preliminary revenue results and the ability of the company to focus and execute this quarter. This is our third consecutive quarter with a book-to-bill over 1, and we are very encouraged by evidence that our customers are getting back to work,” said Jay Flatley, President & CEO of Illumina. “Our annualized HiSeq consumable pull-through grew to approximately $300,000 per instrument in Q1, a very encouraging trend.”

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.